Cor Vasa 2020, 62(5):479-482 | DOI: 10.33678/cor.2020.026

Sacubitril/Valsartan and implantable cardioverter- -defibrillators: evolving therapeutic strategies. A case report

Claudia Morabitoa, Marianna Gigliotti De Fazioa, Michele Scaranob, Vito Maurizio Paratob, Giuseppe Dattiloa, Matteo Casalec
a Department of Clinical and Experimental Medicine, University of Messina, Italy
b Operative Unit of ICCU and Cardiology, Hospital "Madonna del Soccorso", ASUR Marche - Area Vasta 5, San Benedetto del Tronto, Italy
c Operative Unit of ICCU and Cardiology, Hospital "S. Maria della Misericordia", ASUR Marche - Area Vasta 1, Urbino, Italy

Heart failure is a major public health concern, being one of the most common reasons for hospitalization. Its prognosis is poor and the optimal management to date represents a continuous challenge. This case report describes a 67-year-old man with chronic heart failure with reduced ejection fraction (HFrEF), remaining symptomatic despite optimal medical therapy and refusing an implantable cardioverter-defibrillator (ICD) as a prevention for sudden cardiac death. We introduced Sacubitril/Valsartan and after 3 months of treatment we observed a significant improvement in symptoms with reduction of arrhythmic burden and, after six months even of echocardiographic parameters, leading to withdraw the indication to the ICD.

Keywords: ARNI, Cardiac implantable electronic devices, Heart failure, ICD, Sacubitril/Valsartan

Received: April 8, 2020; Revised: April 8, 2020; Accepted: April 14, 2020; Published: November 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Morabito C, De Fazio MG, Scarano M, Parato VM, Dattilo G, Casale M. Sacubitril/Valsartan and implantable cardioverter- -defibrillators: evolving therapeutic strategies. A case report. Cor Vasa. 2020;62(5):479-482. doi: 10.33678/cor.2020.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lee CS, Auld J. Crit Care. Heart Failure: A Primer. Nurs Clin North Am 2015;27:413-425. Go to original source... Go to PubMed...
    2. Banerjee S, McCormack S. Ottawa (ON). Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines. Canadian Agency for Drugs and Technologies in Health; 2019 Aug.
    3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146. Go to original source... Go to PubMed...
    4. Moertl D. Disease management programs in heart failure: half a century of an unmet need. Wien Klin Wochenschr 2017;129:861-863. Go to original source... Go to PubMed...
    5. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129-2200. Go to original source... Go to PubMed...
    6. Khder Y, Shi V, McMurray JJV, Lefkowitz MP. Sacubitril/Valsartan (LCZ696) in Heart Failure. Handb Exp Pharmacol 2017;243:133-165. Go to original source... Go to PubMed...
    7. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014;371:993-1004. Go to original source... Go to PubMed...
    8. Ferreira JP, Metra M, Anker SD, et al. Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. Eur J Heart Fail 2019;21:218-226. Go to original source... Go to PubMed...
    9. Dattilo G, Borgia F, Guarneri C, et al. Cardiovascular Risk in Psoriasis: Current State of the Art. Curr Vasc Pharmacol 2019;17:85-91. Go to original source... Go to PubMed...
    10. De Vecchis R, Paccone A, Di Maio M. Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study. Cardiol Res 2019;10:293-302. Go to original source... Go to PubMed...
    11. Dattilo G, Imbalzano E, Lamari A, et al. Ischemic heart disease and early diagnosis. Study on the predictive value of 2D strain. Int J Cardiol 2016;215:150-156. Go to original source... Go to PubMed...
    12. Williams LK, Urbano-Moral JA, Rowin EJ, et al. Velocity vector imaging in the measurement of left ventricular myocardial mechanics on cardiac magnetic resonance imaging: correlations with echocardiographically derived strain values. J Am Soc Echocardiogr 2013;26:1153-1162. Go to original source... Go to PubMed...
    13. de Gregorio C, Laterra G, Vaccaro V, et al. Time-based clinical and functional achievements in real-life HF patients on ARNI treatment. Eur J Intern Med 2020 Feb 20. doi: 10.1016/j.ejim.2020.02.007. [Epub ahead of print]. Go to original source... Go to PubMed...
    14. Dattilo G, Falanga G, Casale M et al. Oral Anticoagulants: Old and New Therapy. In: Berhardt LV (Ed.). Advances in Medicine and Biology. Volume 83. New York: Nova Science Publishers, Inc.; 2015:13-70.
    15. Casale M, et al. Cardiac implantable devices and takotsubo syndrome. A rare but potential eventuality. Cor Vasa 2018;60:e500-e502 Go to original source...
    16. Scarano M, Gizzi G, Mastrodicasa D, Mantini C. Cardiac implantable electronic devices and chemotherapy: A risky combination. Cor Vasa 2018;60:e469-e471. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes